MedTrace Logo

Effects of Metyrapone in Patients With Hypercortisolism

NCT05255900 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-03-30

No results posted yet for this study

Summary

The aims of the present study are to evaluate in patients with mild hypercortisolism the effect of metyrapone treatment on glycometabolic control, blood pressure, thrombotic risk parameters, lipid profile, bone turnover markers, mental health and cortisol circadian rhythm.

Conditions

  • Hypercortisolism

Interventions

DRUG

Metyrapone Capsules

Exposure to 24 weeks of treatment with metyrapone

Sponsors & Collaborators

  • HRA Pharma

    collaborator INDUSTRY

  • Istituto Auxologico Italiano

    lead OTHER

Principal Investigators

  • Chiodini Chiodini, Professor · Istituto Auxologico Italiano IRCCS

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-28
Primary Completion
2025-06-30
Completion
2025-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05255900 on ClinicalTrials.gov